Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
More gas accumulates
Exogenous antioxidantsdouble-edged swords in cellular redox state
Additional TRIUMPH and Other Phase 3 Trials Lilly has initiated or announced additional Phase 3 trials for retatrutide: Chronic low back pain -- Phase 3 initiated in Q3 2025 Overweight/obesity (additional) -- new Phase 3 trial initiated in Q3 2025 MASLD master protocol (NCT07165028) -- a Phase 3 multi-agent master protocol in MASLD that includes retatrutide (not a dedicated retatrutide-only liver trial), building on the Phase 2 liver fat sub-study TRANSCEND Program -- Type 2 Diabetes TRANSCEND Phase 3 program evaluating retatrutide specifically for type 2 diabetes
Rarely, severe side effects have been reported, such as pancreatitis, medullary thyroid cancer, acute (sudden) kidney injury, and worsening diabetes-related retinopathy
Standard dosing is typically 200300 mcg of each peptide administered together via subcutaneous injection, most commonly 5 nights per week before bedtime
GLP-1s have a low risk of causing hypoglycemia
US$ 29.17
US$ 27.68
US$ 28.82
US$ 22.34
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
